These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33674256)

  • 1. Placebo Response in Patients with Oral Therapy for Overactive Bladder: A Systematic Review and Meta-analysis.
    Mostafaei H; Janisch F; Mori K; Quhal F; Pradere B; Hajebrahimi S; Roehrborn CG; Shariat SF
    Eur Urol Focus; 2022 Jan; 8(1):239-252. PubMed ID: 33674256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men.
    De Nunzio C; Brucker B; Bschleipfer T; Cornu JN; Drake MJ; Fusco F; Gravas S; Oelke M; Peyronnet B; Tutolo M; van Koeveringe G; Madersbacher S
    Eur Urol; 2021 Apr; 79(4):492-504. PubMed ID: 33402296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of medication for treating overactive bladder in patients with Parkinson's disease: a meta-analysis and systematic review of randomized double-blind placebo-controlled trials.
    Cheng B; Huang S; Huang Q; Zhou Z; Bao Y
    Int Urogynecol J; 2023 Sep; 34(9):2207-2216. PubMed ID: 37052644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrical stimulation with non-implanted electrodes for overactive bladder in adults.
    Stewart F; Gameiro OL; El Dib R; Gameiro MO; Kapoor A; Amaro JL
    Cochrane Database Syst Rev; 2016 Apr; 4():CD010098. PubMed ID: 27037009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of overactive neurogenic bladder treatment: A systematic review of randomized controlled trials.
    Bapir R; Bhatti KH; Eliwa A; García-Perdomo HA; Gherabi N; Hennessey D; Magri V; Mourmouris P; Ouattara A; Perletti G; Philipraj J; Stamatiou K; Trinchieri A; Buchholz N
    Arch Ital Urol Androl; 2022 Dec; 94(4):492-506. PubMed ID: 36576454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study).
    Herschorn S; Chapple CR; Abrams P; Arlandis S; Mitcheson D; Lee KS; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Robinson D
    BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nocebo Response in the Pharmacological Management of Overactive Bladder: A Systematic Review and Meta-analysis.
    Mostafaei H; Mori K; Quhal F; Miura N; Motlagh RS; Pradere B; Laukhtina E; Lysenko I; Ghaffari S; Hajebrahimi S; Shariat SF
    Eur Urol Focus; 2021 Sep; 7(5):1143-1156. PubMed ID: 33153953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The placebo effect in overactive bladder syndrome.
    Mangera A; Chapple CR; Kopp ZS; Plested M
    Nat Rev Urol; 2011 Jul; 8(9):495-503. PubMed ID: 21727941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine.
    Sebastianelli A; Russo GI; Kaplan SA; McVary KT; Moncada I; Gravas S; Chapple C; Morgia G; Serni S; Gacci M
    Int J Urol; 2018 Mar; 25(3):196-205. PubMed ID: 29205506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment for overactive bladder: A meta-analysis of tibial versus parasacral neuromodulation.
    Wang ZH; Liu ZH
    Medicine (Baltimore); 2022 Oct; 101(41):e31165. PubMed ID: 36253991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH).
    Kakizaki H; Lee KS; Yamamoto O; Jong JJ; Katou D; Sumarsono B; Uno S; Yamaguchi O
    Eur Urol Focus; 2020 Jul; 6(4):729-737. PubMed ID: 31718957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin injections for adults with overactive bladder syndrome.
    Duthie JB; Vincent M; Herbison GP; Wilson DI; Wilson D
    Cochrane Database Syst Rev; 2011 Dec; (12):CD005493. PubMed ID: 22161392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which anticholinergic drug for overactive bladder symptoms in adults.
    Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
    Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vibegron, a Novel Potent and Selective β
    Yoshida M; Takeda M; Gotoh M; Nagai S; Kurose T
    Eur Urol; 2018 May; 73(5):783-790. PubMed ID: 29366513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A; Wyndaele JJ; Sieber P
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of Vibegron in treating overactive bladder: A systematic review and pooled analysis of randomized controlled trials.
    Shi H; Chen H; Zhang Y; Cui Y
    Neurourol Urodyn; 2020 Jun; 39(5):1255-1263. PubMed ID: 32421908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR).
    Wagg A; Staskin D; Engel E; Herschorn S; Kristy RM; Schermer CR
    Eur Urol; 2020 Feb; 77(2):211-220. PubMed ID: 31733990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials.
    Cui Y; Zong H; Yang C; Yan H; Zhang Y
    Int Urol Nephrol; 2014 Jan; 46(1):275-84. PubMed ID: 23896942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.